Market Currents
A diabetes pill developed by Bristol-Myers (BMY) and AstraZeneca (AZN) was effective in a Phase...
-
Sunday, June 26, 2011, 5:35 AM ETA diabetes pill developed by Bristol-Myers (BMY) and AstraZeneca (AZN) was effective in a Phase III study, although the trial produced increased cases of bladder and breast cancers. The drug, dapagliflozin, is set to be reviewed by an FDA advisory committee in July.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 6 comments:
Drug stock you should be talking about is in the BB.
ELTP. It has an amazing chart.
Great potential in the oxy market. That market has been in the news as of lately (ACUR PTIE DRXX).
This stock just traded past its 50 Moving average. Conference call this week.
ELTP to double/ triple in the next few weeks.